101. Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients
- Author
-
Thomas Foiadelli, Claudio Panarese, Antonio Uccelli, Margherita Nosadini, Pietro Annovazzi, Ramona Cordani, Elisa De Grandis, Diego Franciotta, Lino Nobili, Paola Camicione, Paolo Capris, Maria Cellerino, Matteo Gastaldi, Maria Margherita Mancardi, Stefano Sartori, Angela Pistorio, Thea Giacomini, Giulia Prato, Salvatore Savasta, Andrea Rossi, Giovanni Morana, and Paola Lanteri
- Subjects
medicine.medical_specialty ,Visual acuity ,VEP abnormalities ,pediatrics ,Acquired demyelinating syndromes of the central nervous system ,Myelin oligodendrocyte glycoprotein ,Optic disc swelling ,Spectral domain optical coherence tomography ,Optic neuritis ,Fundus (eye) ,03 medical and health sciences ,0302 clinical medicine ,children ,immune system diseases ,Median follow-up ,Internal medicine ,MOG ,Medicine ,030212 general & internal medicine ,Expanded Disability Status Scale ,biology ,business.industry ,Multiple sclerosis ,Optic neuritis, pediatrics, children, MOG ,General Medicine ,medicine.disease ,nervous system diseases ,Neurology ,Cohort ,biology.protein ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
recent studies reported that anti myelin oligodendrocyte glycoprotein (MOG) antibody (ab) related optic neuritis (ON) tend to have characteristics that differ from seronegative ones. The aim of our study was to investigate the clinical characteristics of pediatric anti-MOG ON by comparing anti MOG-ab-seropositive and seronegative patients with ON.in this retrospective Italian multicentre study, participants were identified by chart review of patients evaluated for acquired demyelinating syndromes of the central nervous system (over the period 2009-2019). We selected patients presenting with ON as their first demyelinating event. Inclusion criteria were age 18 years at symptoms onset; presentation consistent with ON; negativity of anti-aquaporin 4 antibodies (AQP4). Only patients who were tested for MOG-IgG1-ab with a live cell-based assay were included.22 patients (10 MOG-ab-positive and 12 MOG-ab-negative) were included. Fundus oculi examination at onset showed disc swelling in 9/10 in the MOG-ab-positive cohort and 2/10 in the seronegative group (P = 0.002). Retinal Fiber Nerve Layer (RFNL) thickness measured by Spectral Domain Optical Coherence Tomography (S-OCT) was increased in the 5/5 MOG-ab-positive patients tested and was normal or reduced in the seronegative patients tested (4/4 patients) (P = 0.024). Visual acuity impairment at onset did not differ significantly between the two groups, but the MOG-ab-positive cohort showed better recovery at follow-up both regarding visual acuity (P = 0.025) and expanded disability status scale (EDSS) (P = 0.013). A final diagnosis of MS was frequent among seronegative patients (6/12, 50%), whereas none of the MOG-ab-positive group received a diagnosis of MS (P = 0.015). Clinical relapse frequency was low in both groups: 2/10 MOG-ab-positive and 2/12 seronegative cases relapsed, with a median follow up of 25 months.optic disc swelling and increased RFNL at baseline are strongly associated with MOG-ab positivity. MOG-ab-positive patients with ON showed better recovery compared to the seronegative ones. The relapse rate was low and did not differ among the two groups.
- Published
- 2019